VivoSim Labs (FRA:4OR) Notes Receivable: €0.00 Mil (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.13
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Notes Receivable?

VivoSim Labs FRA:4OR 39 Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review.

VivoSim Labs's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

VivoSim Labs Notes Receivable Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Notes Receivable Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
VivoSim Labs (FRA:4OR) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Notes Receivable too high?
VivoSim Labs' current Notes Receivable is €0.00 Mil. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Notes Receivable compare to AZTR and GRI?
VivoSim Labs' Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Notes Receivable is €0.00 Mil. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.

Key valuation signals for FRA:4OR:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.13
GF Value